This study was designed to determine the biochemical effect of curcumin nano-suspension on alleviating metabolic disorders in experimentally induced diabetic rats. An experimental diabetic rat model was induced by 60mg/kg body weight of streptozoticin (STZ) as a single dose. Curcumin nano-suspension was administrated orally at a dose of 300mg/kg body weight daily for 56 days. Metabolic profile was examined biochemically. Administration of curcumin nano-suspension decreases CK-MB, LDH and AST serum values in STZ- diabetic rats treated with curcumin nano-suspension (203±5.04 and 604±12.85; 1910±7.97 and 4739±120.17, and 125± 12.13 and 174 ± 16.10) respectively, when compared to untreated diabetic rats, it decreases triacylglycerol in serum (124±2.01 and 144±11.4mg/dl) compared to the diabetic rats also, with not so much increase the body weight (242±4.94 and214±18.04gm). On the other hand, there were no changes in concentrations of glucose (346.50±11.04 and 329.50±42.86mg/dl); insulin (0.92±0.66 and1.10±0.18μl/ml) and the total cholesterol level (105±5.04and 112±17.18mg/dl) in serum compared to diabetic rats. In conclusion, oral ingestion of curcumin nano-suspension reverses side effects result from metabolic disorders in streptozotocin induced diabetic rats via its anti-inflammatory and hypolipidemic role.